Compare Lionsgate Studios Corp Common Shares (LION) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Novartis AG — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.24B), while Novartis AG trades at $148.84 (market cap $279.90B). The key difference: Novartis AG is far larger — about 86.4× Lionsgate Studios Corp Common Shares's market cap, and Novartis AG pays a 3.23% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Novartis AG for 82 Days on average.
| LION | NVS | |
|---|---|---|
Market Cap | $3.24B | $279.90B |
Volume | 3,214,595 | 1,647,300 |
Sector | Technology | Health |
52-Week High | $16.40 | $168.62 |
52-Week Low | $5.91 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $6.75B | $321.22B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
